Phase 2 Completed N=74 Randomized Treatment

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

leukemia

Source: ClinicalTrials.gov NCT00795002 ↗

Enrolled (actual)

Serious AEs

20.5%

Results posted

Dec 2013

Primary outcomePrimary: Complete Response — 24; 29 participants

Summary

This randomized phase II trial is studying two different schedules of alvocidib to compare how well they work when given together with cytarabine and mitoxantrone in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as alvocidib, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which schedule of alvocidib is more effective when given together with cytarabine and mitoxantrone in treating patients with acute myeloid leukemia.

Outcome Measures

Outcome	Result	p-value
PRIMARY Complete Response	24; 29	—
SECONDARY Number of Participants Experiencing Death From Any Cause Within 60 Days of Starting FLAM	3; 3	—
SECONDARY Disease-free Survival	13.6; 12.0	—

Eligibility Criteria

Inclusion Criteria

Pathologically confirmed newly diagnosed acute myeloid leukemia (AML) meeting the following criteria:
Subtypes M0, M1, M2, M4-7
No acute promyelocytic leukemia (M3)
At least 50 years of age OR >= 18 years of age with >= 1 of the following poor-risk disease features:
Antecedent hematologic disorder, including myelodysplastic syndromes (MDS)-related AML or prior myeloproliferative disorder (MPD)
Treatment-related AML, AML with trilineage dysplasia
Myeloid sarcoma, myeloid proliferations related to Down Syndrome, or blastic plasmacytoid dendritic cell neoplasm
AML with trilineage dysplasia
AML with adverse cytogenetics (defined as -5/-5q; -7/-7q; abnormal 3q, 9q, 11q, 20q, 21q, or 17p; t[6;9]; t[9;22]; trisomy 8; trisomy 13, complex karyotypes [>= 3 unrelated abnormalities]),
No hyperleukocytosis with >= 50, 000 blasts/uL (leukapheresis or hydroxyurea allowed for cytoreduction immediately prior to the first dose of alvocidib)
No active CNS leukemia
ECOG performance status 0-2
Serum creatinine = = 45%

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00795002). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.